Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Paclitaxel in Gastric or Gastroesophageal Cancer
NCT04220827Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2019
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events. Started Dec 2019; status: active, not recruiting.
02
Drugs
paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04220827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220827.